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SpainAbstractThe IFNL4 ss469415590 polymorphism, in high linkage
disequilibrium with the IL28B rs12979860 variant, has been
associated with hepatitis C virus clearance. We evaluated whether
ss469415590 is associated with clinical and immunovirological
parameters in human immunodeﬁciency virus-infected subjects.
We found an independent association of the IFNL4 ss469415590
polymorphism with higher prevalence of AIDS-deﬁning illnesses
and lower CD4 T cell numbers. These results suggest the
existence of common host defence mechanisms against different
viral infections.
Clinical Microbiology and Infection © 2014 European Society of
Clinical Microbiology and Infectious Diseases. Published by
Elsevier Ltd. All rights reserved.
Keywords: AIDS, CD4, HIV infection, IFNL4, IL28B
Original Submission: 6 May 2014; Revised Submission: 10
October 2014; Accepted: 12 October 2014Clinical Microbiology and Infection © 2014 European Society of CEditor: G. Antonelli
Article published online: 29 October 2014linicCorresponding author: E. Ruiz-Mateos, Laboratory of Immuno-
virology, Biomedicine Institute of Seville, Clinic Unit of Infectious
Diseases, Microbiology and Preventive Medicine, Virgen del Rocío
University Hospital, IBIS/CSIC/SAS/University of Seville, Avd. Manuel
Siurot s/n, Seville 41013, Spain
E-mail: ezequiel.ruizmateos@gmail.com
M. Leal and E. Ruiz-Mateos contributed equally to this workIntroductionThe single nucleotide polymorphism rs12979860, located close
to the gene, which encodes interferon λ3 (IFN-λ3), also known
as IL28B [1,2], was associated with both spontaneous and
treatment-induced clearance of hepatitis C virus (HCV) [3,4].
We showed that the favourable genotype IL28B-CC was
associated with spontaneous control of human immunodeﬁ-
ciency virus (HIV) viremia [5], opposite to ﬁndings in cohorts of
African-Americans [6,7].
Recently, a dinucleotide variant, ss469415590 (TT or ΔG),
which is in high linkage disequilibrium with IL28B rs12979860,
was discovered [8,9]. The ΔG variant creates a novel gene,
designated IFNL4, encoding the IFN-λ4 protein, similar in
structure to IFN-λ3 [8]. IFNL4 ss469415590 seems to be the
functional polymorphism, as it is associated with the production
of IL28B [9]. When compared to rs12979860, ss469415590 is
more strongly associated with the spontaneous clearance of
HCV infection and the response to HCV treatment [8–11].
Whether ss469415590 is associated with clinical and immu-
novirological parameters in HIV-infected patients is unknown.
The aim of the present study was to analyse the association
of the IFNL4 variants with clinical and immunovirological pa-
rameters in HIV-infected antiretroviral therapy-naïve patients.MethodsPatients included in this cross-sectional study were Caucasian
and belonged to the HIV-infected seroprevalent cohort of the
Infectious Diseases Service at Virgen Del Rocío University
Hospital (Seville, Spain). A total of 388 chronic, asymptomatic
HIV-infected patients, naïve for antiretroviral treatment and with
available CD4 T cell data and peripheral blood mononuclear cellClin Microbiol Infect 2015; 21: 289.e1–289.e4
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included. Clinical and immunovirological data including CD4 T
cell numbers, AIDS-deﬁning illness prevalence, and viral load
were recorded at the time of entry into the cohort. AIDS-
deﬁning illnesses were those considered Stage C according to
the Centers for Disease Control and Prevention (http://hab.hrsa.
gov/deliverhivaidscare/clinicalguide11). All of the patients
participating in the study gave their informed consent, and the
institutional ethics committees approved the protocols (proto-
col number: 2012PI/240).ResultsThe characteristics of the subjects are summarized in Table 1.
The distribution of IFNL4 genotypes was consistent with the
Hardy-Weinberg equilibrium (p > 0.05). The proportion of
individuals with AIDS-deﬁning illness was higher in carriers of
the ΔG variant (TT/TT: 4.9%; TT/ΔG: 9.6%; and ΔG/ΔG: 19.5%;
TT/TT vs. TT/ΔG, p 0.085; TT/TT vs. ΔG/ΔG, p 0.002; TT/TT
vs. TT/ΔG and ΔG/ΔG, p 0.021). After adjusting by age, CD4 T
cell numbers, HCV exposition, and HIV viremia in the multi-
variate analysis, the IFNL4 ss469415590 remained indepen-
dently associated with the proportion of subjects with AIDS-
deﬁning illnesses (Table 2).
We also analysed which factors were related to CD4 T cell
numbers. When we stratiﬁed by subjects with CD4 T cell
150 cell/μL, higher CD4 T cell numbers were observed in




Number of subjects 388 185 (47.8)
Gender (male) (%) 320 (82.5) 159 (85.9)
Age (years) 32 [28–40] 32 [27–40]
CD4 T cell count/μL 397 [216–570] 412 [198–593]
Nadir CD4 T cell count/μL 308 [186–439] 308 [177.5–442]
Log HIV RNA copies/mLa 4.60 [4.05–5.12] 4.56 [3.95–5.17]
AIDS-deﬁning illnessb 32 (8.2) 9 (4.9)
Anti-HCV detected (%)c 96/358 (26.8) 49/174 (26.5)
HCV RNA detected (%)d 67/83 (80.7) 30/43 (69.8)
HCV spontaneous clearancee 16/83 (19.3) 13/43 (30.2)
HLA-B57+ subjectsf 18/255 (7.0) 7/123 (5.7)
HCV, hepatitis C virus; HLA, human leukocyte antigens; NA, not applicable; PCR, polymera
Statistical χ2 test and Student’s t test were used to analyse differences between categorical
statistically signiﬁcant. All of the continuous variables were expressed as the median [interqua
and percentages.
*Comparison between TT/TT and ΔG/TT genotype.
**Comparison between TT/TT and ΔG/ΔG genotype.
Qualitative variables are shown as numbers and percentages of individuals; quantitative varia
aHIV viral load measures were available in 287 subjects who had visited our unit since 1997
bType and prevalence of AIDS-deﬁning illnesses were: Tuberculosis (pulmonary or extrapul
sarcoma, 4/32 (12.5%); Burkitt lymphoma, 3/32 (9.4%); esophageal Candidiasis, 2/32 (6.3%);
recurrent Salmonella septicemia, 1/32 (3.1%); Mycobacterium (othe spp.) pulmonary disease 1
cAnti-hepatitis C virus data were available in 358 individuals.
dPCR data for HCV was available in 83/96 patients.
eHCV spontaneous clearance refers to the subjects who cleared HCV infection without HC
fHLA typing was assayed in patients where DNA samples were available (n = 255).
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectsubjects (p 0.007). In a multivariate analysis after adjusting by
HIV viremia, age, and AIDS-deﬁning illness, IFNL4 ss469415590
remained independently associated with CD4 T cell counts
(Table 2).
However, when we analysed the 287 patients for whom HIV
viremia measurements were available, IFNL4 genotypes were
not associated with plasmatic viral load (data not shown). On
the contrary, as expected, logistic regression analysis indicated
that IFNL4-TT/TT was the only variable independently associ-
ated with spontaneous clearance of HCV, despite the low
number of patients (p 0.015, OR 5.176, 95% CI 1.367–19.593).DiscussionIn this cross-sectional study, the results showed that the IFNL4-
ΔG variant is associated with unfavourable clinical and immu-
nological status independently of HIV viremia. We also
conﬁrmed the association of the IFNL4-TT/TT genotype with
spontaneous clearance of HCV in HIV/HCV co-infection [10].
These results suggest the existence of common host defence
mechanisms against different viral infections, with the level of
protection related to the intrinsic characteristics and immu-
nopathogenesis of each virus.
The most relevant ﬁnding in our study was the association of
ss469415590 with AIDS-deﬁning illness prevalence. However, a
limitation of our study is the lack of awareness of the date of
HIV infection in this HIV-seroprevalent cohort. We also
observed an association with improved immunological status inp* p**ΔG/TT ΔG/ΔG
167 (47.7) 36 (9.3) NA NA
132 (79.0) 29 (80.6) 0.087 0.406
32 [28–40] 33 [28–42] 0.509 0.394
372 [224–565] 368 [210–501] 0.228 0.392
310 [194–429] 305 [168–459] 0.774 0.940
4.64 [4.05–5.05] 4.60 [4.08–5.29] 0.899 0.201
16 (9.6) 7 (19.4) 0.085 0.002
40/150 (26.7) 7/34 (20.6) 0.764 0.363
32/35 (91.4) 5/5 (100) 0.018 0.150
3/35 (8.6) 0/5 (0) 0.020 0.120
8/115 (7.0) 3/17 (17.6) 0.688 0.073
se chain reaction.
variables and continuous variables, respectively. p Values <0.05 were considered
rtile range (IQR)], and the categorical variables were expressed as the number of cases
bles are displayed as median and interquartile ranges (IQR).
; HIV viral load measurements were not available before this date.
monary), 13/32 (40.6%); Pneumocystis jiroveci pneumonia (PCP), 6/32 (18.8%); Kaposi
HIV-related encephalopathy, 1/32 (3.1%); recurrent bacterial pneumonia, 1/32 (3.1%);
/32 (3.1%).
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TABLE 2. The IFNL4 ss469415590 is independently associated with AIDS-deﬁning illnesses and CD4 T cell count
Characteristics
AIDS-deﬁning illness CD4 T cell counta
Bivariate analysis Multivariate analysis Bivariate analysis Multivariate analysis
p OR 95% CI p OR 95% CI p B 95% CI p B 95% CI
Gender (male) 0.438 1.534 0.520–4.527 0.905 4.407 −67.902–76.716
Age (years) <0.001 1.063 1.028–1.099 0.007 1.063 1.017–1.112 0.002 −4.897 −7.914–1.881 0.073 −2.564 −5.370–0.241
CD4 T cell count/μL <0.001 0.994 0.991–0.996 0.003 0.995 0.992–0.998 NA NA NA NA NA NA
AIDS-deﬁning illness NA NA NA NA NA NA 0.020 −161.412 −297.556–25.269 0.680 −29.564 −170.688–111.559
Log HIV RNA copies/mL 0.002 2.804 1.464–5.374 0.249 1.546 0.737–3.242 <0.001 −57.818 −88.349–27.349 <0.001 −55.987 −86.651–25.324
Anti-HCV detected 0.593 1.252 0.549–2.853 0.998 −0.088 −66.030–65.854
IFNL4-ss469415590b 0.016 0.003 NA NA
TT/TTc
ΔG/TT 0.091 2.072 0.890–4.824 0.010 5.482 1.503–19.991 0.011 −75.685 −135.795–17.575 0.047 −57.628 −114.398–0.858
ΔG/ΔG 0.004 4.720 1.631–13.665 0.001 14.066 2.955–66.967 0.072 −88.929 −185.882– .024 0.316 −47.383 −140.207–45.441
B, regression coefﬁcient; CI, conﬁdence interval; NA, not applicable; OR, odds ratio.
Bivariate and multivariate logistic and linear regression analyses were performed using AIDS-deﬁning illness (left) and CD4 T cell levels (right) as dependent variables, respectively.
aThree hundred twenty-ﬁve subjects with CD4 150 cell/μL were included: 148 were TT/TT; 145 TT/ΔG, and 32 ΔG/ΔG.
bp Value of the overall correlation, this can be applied only to a logistic regression analysis (dependent variable: AIDS-deﬁning illness).
cTT/TT is the reference genotype, hence, p values, odds ratio, conﬁdence interval (logistic regression), B value, and conﬁdence interval (linear regression) can only be shown for ΔG/
TT and ΔG/ΔG genotypes. p Values <0.05 were considered statistically signiﬁcant.
CMI Machmach et al. IFNL4 in HIV-infected individuals 289.e3carriers of the favourable allele for ss469415590. The fact that
this association was observed in subjects with CD4 T cell
counts 150 cell/μL suggests that the protective effect of these
alleles is transient and/or may require the involvement of other
genetic factors or immunological mechanisms. The absence of
differences in HIV viremia between IFNL4 variants suggests that
the effect of this polymorphism on HIV viremia depends on
other factors, such as HLA-B57 (in fact, the only variables
independently associated with viral load levels were HLA-B57
and CD4 T cells, data not shown), or that the effect may
only occur early in the infection. In addition, we found that
IFNL4-TT/TT was associated with spontaneous clearance of
HCV, in agreement with a previous study we found that 100%
of the individuals who spontaneously cleared HCV carried the
TT allele [10].
A possible explanation for our results may be a defect in
IL28B/IFN-λ3 production and/or impaired activity in carriers of
the unfavourable alleles of rs12979860 and/or ss469415590, as
previously suggested [9]. We suggest that in addition to its
antiviral activity [3], IL28B/IFN-λ3 may also be a regulator of the
adaptive immune response. In fact, using IL28B/IFN-λ3 as an
adjuvant for HIV DNA vaccination, Morrow et al. demon-
strated that IL28B/IFN-λ3 has potent effects on antigen-speciﬁc
responses, inducing an increase in the T helper-1 cell response
[12]. On the other hand, Prokunina-Olsson et al. suggested that
only carriers of the IFNL4-ΔG variant express the IFN-λ4
protein, which may compete with the IL28B/IFN-λ3 receptors
and apparently cause a preactivation of the interferon-
stimulated genes, which reduces responsiveness to type I and
III interferon [8]. These data may explain antiviral and immu-
nomodulatory defects in carriers of the IFNL4-ΔG variant. In
these subjects, IFN-λ4 production may impair an adequate
immune response to opportunistic pathogens, which explainsClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Inthe higher prevalence of AIDS-deﬁning illness observed in our
study.
In summary, the association of IFNL4 genotypes with clinical
and immunological parameters related to HIV disease pro-
gression suggests the existence of common host mechanisms
against different viral infections [5]. Elucidation of the mecha-
nisms of action of IFN-λ3 and -λ4 may allow the development
of therapeutic interventions not only for HCV, but also for HIV
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